Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.

Home > Investor Relations

Investor Conference on FY2017 2Q Financial Results

Jul 28, 2017

Jul 31: Webcast of Investor Conference on FY2017 2Q Financial Results
Jul 28: Investor Conference on FY2017 2Q Financial Results
Jul 27: Financial Results for Second Quarter of Fiscal Year 2017 (January - June, 2017)
Jul 20: Events & Presentations has been updated with the Time of the Financial Results
Jul 14: Webcast of R&D Conference Call (ISTH 2017)

More

Sep 11

Contribution of Para-transit Vehicles to Welfare Services

[

PDF 190KB]

Sep 08

Filing of Lawsuit on Patent Infringement Concerning Herceptin^® Injection, and a Petition for Provisional Disposition Order

[

PDF 62KB]

Aug 25

Approval of Actemra^®for Additional Indications of
Takayasu Arteritis and Giant Cell Arteritis,
Both are Designated Intractable Diseases

[

PDF 66KB]

Aug 24

Chugai’s Emicizumab Receives Priority Review Designation by FDA
for Hemophilia A with Inhibitors

[

PDF 108KB]

Aug 23

New Drug Application Filed for Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab

[

PDF 35KB]

More

Management Policy

R&D

Events & Presentations

Events & Presentations

Shareholder Information

TSE Code:4519

Share Graph

Annual Report 2016 (Integrated Edition Including CSR Report)
[ 9.6MB]

Supplementary Materials

Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following "Terms and Conditions of Website Use."

Copyright © Chugai Pharmaceutical Co., Ltd. All rights reserved.